IMVT vs. ITCI, VTRS, MRNA, RDY, PCVX, SRPT, QGEN, ASND, ROIV, and RVMD
Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.
Immunovant vs.
Immunovant (NASDAQ:IMVT) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability.
Intra-Cellular Therapies has higher revenue and earnings than Immunovant. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.
Immunovant currently has a consensus target price of $45.90, suggesting a potential upside of 115.90%. Intra-Cellular Therapies has a consensus target price of $103.62, suggesting a potential downside of 19.43%. Given Immunovant's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunovant is more favorable than Intra-Cellular Therapies.
Immunovant has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Immunovant's return on equity.
In the previous week, Intra-Cellular Therapies had 9 more articles in the media than Immunovant. MarketBeat recorded 13 mentions for Intra-Cellular Therapies and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.16 beat Intra-Cellular Therapies' score of 0.45 indicating that Immunovant is being referred to more favorably in the media.
Intra-Cellular Therapies received 395 more outperform votes than Immunovant when rated by MarketBeat users. However, 78.40% of users gave Immunovant an outperform vote while only 66.92% of users gave Intra-Cellular Therapies an outperform vote.
47.1% of Immunovant shares are owned by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 5.9% of Immunovant shares are owned by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Immunovant has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.
Summary
Intra-Cellular Therapies beats Immunovant on 9 of the 17 factors compared between the two stocks.
Get Immunovant News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunovant Competitors List
Related Companies and Tools
This page (NASDAQ:IMVT) was last updated on 2/22/2025 by MarketBeat.com Staff
Free IMVT Stock Alerts